HUM has delivered sharply stronger price momentum, up roughly 70% year-to-date, versus about 18% for UNH . UNH offers greater diversification and a more stable earnings profile through its Optum health-services business, while HUM is a near pure-play on Medicare Advantage (MA).
CVS is showing the clearest fundamental momentum, with recent operating income growth accelerating sharply on an Aetna and Medicare Advantage margin recovery. HUM is absorbing a sizable near-term earnings headwind from Medicare Stars ratings, even as its 2026 membership growth has been strong.
CB has demonstrated stronger recent momentum, backed by record earnings, disciplined underwriting, and active share buybacks. UNH offers deep-value positioning and a large-scale recovery narrative but remains weighed down by regulatory scrutiny and elevated medical costs.
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
CNC is the largest Medicaid managed-care provider in the United States, while UNH is the nation's largest health insurer, pairing its UnitedHealthcare insurance arm with the Optum health-services platform. Both stocks are in a recovery phase after a difficult 2025, but CNC has shown materially stronger relative performance, more than doubling off its 52-week low on improving margins and favorable policy signals.
Centene ( CNC ) has delivered dramatically stronger relative performance over the past year, while Elevance Health ( ELV ) has produced steadier, less volatile gains. Both are U.S. managed-care insurers, but CNC is heavily concentrated in government programs (Medicaid, Medicare, and Marketplace), whereas ELV runs a more diversified model spanning commercial, government, and Carelon services.
Centene Corporation ( CNC ) is the largest Medicaid-focused managed care organization with heavy exposure to the Affordable Care Act (ACA) Marketplace, while Humana Inc. ( HUM ) is the largest pure-play Medicare Advantage (privately managed Medicare) insurer. Both stocks have rallied sharply over the past year, but CNC has posted consecutive earnings beats and guidance raises, whereas HUM remains in a reset year with adjusted earnings guided down roughly 45% year over year.
Centene Corporation (CNC) is a large, government-sponsored managed care leader anchored in Medicaid and Affordable Care Act (ACA) marketplace plans, while Oscar Health (OSCR) is a faster-growing, technology-enabled insurer concentrated in the individual ACA market. Both stocks have rallied strongly in recent months, but OSCR has posted the sharper relative performance, roughly doubling year-to-date versus a strong but smaller gain for CNC .
Margin recovery is the central theme ahead. Centene's Marketplace (ACA exchange) business is targeting a roughly 5% pre-tax margin in 2026, a nearly 600-basis-point improvement from 2025, positioning it for further expansion in 2027. Medicare Advantage (MA) turnaround is running ahead of schedule. Management now expects MA to reach breakeven in 2026 — a year earlier than planned — with the company narrowing its footprint toward dual-eligible and complex populations to prioritize margin over membership growth.
Tickeron AI Verdict: Based on trend consistency, momentum, and relative positioning, Tickeron's AI currently favors CNC over MOH . Both companies are government-sponsored managed care insurers, but CNC is far larger, with a market capitalization roughly three times that of MOH .
Centene shares rose +5.00% to $74.83 from Friday's $71.27 close, with the advance occurring during Monday's regular session after the stock gapped up roughly +4% in premarket trading. The catalyst was regulatory: CMS said late Friday that states may adopt an optional transition period through June 30, 2027 before enforcing new Medicaid work requirements, easing disenrollment fears in Centene's largest segment.
ELV is a larger, more diversified health benefits company, while MOH is a Medicaid-focused managed care operator with a smaller, more concentrated footprint. Elevance Health raised its 2026 adjusted earnings guidance in recent weeks and trades near its 52-week high, reflecting stronger recent earnings momentum.
CNC and MOH are both government-sponsored managed care organizations, but Centene is the far larger player with a market capitalization roughly three times that of Molina. Centene has delivered stronger recent relative performance, more than doubling off its 52-week low, while Molina's recovery has been more volatile after a sharp fourth-quarter 2025 setback.
Molina Healthcare shares climbed to $228.92 from a $209.49 previous close, a +9.27% gain during Monday's regular session, as of 3:11 PM ET. The catalyst was regulatory: CMS said Friday that states may opt into a "hold harmless" period through June 30, 2027 before enforcing new Medicaid work requirements, deferring the enrollment losses that threatened Medicaid-focused insurers' 2027 revenue.
2026 is positioned as a trough year for Molina's Medicaid margins, with management and much of the Street anticipating a multi-year recovery as state rate-setting catches up to medical cost trend. The Florida contract ramp is a major growth catalyst , adding roughly $6 billion in annual premium revenue beginning in late 2026, alongside delayed Georgia and Texas awards expected in late 2027 or 2028.
Both CLOV and OSCR are technology-driven health insurers enjoying strong revenue growth and momentum, but they operate in different markets: CLOV focuses on Medicare Advantage seniors, while OSCR focuses on the Affordable Care Act (ACA) individual market. OSCR is larger, more established, and already generating substantial profits, while CLOV is smaller and earlier in its profitability inflection, with faster relative membership growth.
CVS is navigating a major structural shift, having announced plans to split its retail pharmacy business from its Aetna insurance and Caremark pharmacy benefits operations. UNH has shown more consistent momentum, rebuilding margins after a difficult stretch while raising its full-year earnings outlook in consecutive quarters.
Tickeron AI Verdict: CNC — based on trend consistency, earnings stability, and a lower-risk profile, Centene is the ticker of choice in this comparison. CNC is a large, diversified managed-care operator with recovering margins, while OSCR is a higher-growth, technology-driven insurer focused on the individual market.
Centene's Medicare Advantage (MA) business is now on track to reach breakeven in 2026, roughly a year ahead of plan, positioning margin expansion as the central 2027 story. The commercial Marketplace segment is expected to finish 2026 at the top of its 4.5%–5% pre-tax margin range, a roughly 600-basis-point improvement from 2025.
The central target used here is $37 , the arithmetic mean of nine verified analyst price targets for Oscar Health, Inc. (OSCR) . At the latest verified price of roughly $32.14, reaching $37 would require an advance of about 15% .